Gainers & Losers Of The Day: ACST, MRNS, BIOA, APTO, PULM...

Marinus Pharmaceuticals Inc. has reported positive preliminary data from its phase II trial of Ganaxolone in children with CDKL5 genetic disorder.

from RTT - Biotech http://ift.tt/2jjLioC
via IFTTT